Cambrex Appoints Dottie Donnelly-Brienza as Senior Vice President and Chief Human Resources Officer
25 Juin 2019 - 2:00PM
Cambrex Corporation (NYSE: CBM), the leading small molecule company
providing drug substance, drug product and analytical services
across the entire drug lifecycle, today announced that Dottie
Donnelly-Brienza has been appointed Senior Vice President and Chief
Human Resources Officer. In this new role, she will have global
responsibility for the company’s human resources function, and will
join the company’s executive management team.
Ms. Brienza has over 20 years’ HR experience in
the life sciences sector, and joins Cambrex from Cantel Medical
where she was most recently Chief Human Resources Officer. She has
also held a number of leadership and senior executive roles at
Johnson & Johnson, as well as Merck and Bristol-Myers Squibb.
She has a Master of Science degree in Organization Development and
Applied Human Behavior from the American University in Washington,
DC and a bachelor’s degree from Marywood University, Scranton,
PA.
“Dottie is a highly successful executive with
substantial leadership experience in human resources and has
extensive experience in the healthcare industry,” commented Steven
Klosk, President and Chief Executive Officer at Cambrex. “She joins
Cambrex at an exciting time for the company and will add tremendous
value as we continue to focus on our growth strategy.”
About Cambrex
Cambrex is the leading small molecule company
that provides drug substance, drug product and analytical services
across the entire drug lifecycle. The company provides customers
with an end-to-end partnership for the research, development and
manufacture of small molecule therapeutics. With over 35 years’
experience and a growing team of over 2,000 experts servicing
global clients from sites in North America and Europe, Cambrex is a
trusted partner in branded and generic markets for API and dosage
form development and manufacturing.
Cambrex offers a range of specialist drug
substance technologies and capabilities including biocatalysis,
continuous flow, controlled substances, solid state science,
material characterization and highly potent APIs. In addition,
Cambrex can support conventional dosage forms including oral
solids, semi-solids and liquids and has the expertise to
manufacture specialist dosage forms such as modified-release, fixed
dose combination, pediatric, bi-layer tablets, stick packs,
topicals, controlled substances, sterile and non-sterile
ointments.
For more information, please visit
www.cambrex.com
Contact:
Alex
Maw
Director, Marketing and
Communications
Tel: +44 7803 443
155
Email: alex.maw@cambrex.com
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Cambrex (NYSE:CBM)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024